CT体成分挑战肥胖结直肠手术患者按体重分层抗生素预防
该前瞻性研究纳入153例接受择期结直肠手术的肥胖成人,评估CT体成分与肾功能对头孢唑林手术部位浓度的预测价值。结果显示体重和BMI未改善模型性能,皮下脂肪面积(SFA)预测组织暴露,肌酐清除率(CLcr)预测药物清除。基于SFA≥500 cm2或≥300 cm2且CLcr≥90 mL/min的修订框架较现行体重分层可多识别10%-14%需调整剂量的患者。
要点
- 现行按体重≥120 kg升级至3 g的头孢唑林预防策略对肥胖患者靶达标率仅78%-84%。
- CT测得的皮下脂肪面积(SFA)预测组织暴露,肌酐清除率(CLcr)预测药物清除。
- SFA≥500 cm2或SFA≥300 cm2且CLcr≥90 mL/min的框架可识别更多剂量不足相关SSI风险患者。
核心结论
- 头孢唑林手术部位暴露由局部脂肪分布和肾功能共同决定,现行≥120 kg体重阈值不能准确反映药物分布。
研究设计与样本
- 前瞻性研究,纳入153例接受择期结直肠手术并接受头孢唑林预防的肥胖成人,其中58例用于模型开发、95例用于前瞻性评估,并包含独立外部队列验证。
主要发现
- 体重和BMI未改善模型预测性能。
- 皮下脂肪面积(SFA)预测组织暴露,肌酐清除率(CLcr)预测药物消除。
- 现行体重分层方案靶达标率为78%-84%。
- 修订框架(SFA≥500 cm2或SFA≥300 cm2且CLcr≥90 mL/min)可额外识别10%-14%需剂量调整的患者。
关键数值与推荐
- 现行指南推荐体重≥120 kg时头孢唑林剂量从2 g升至3 g。
- 修订框架采用SFA≥500 cm2或SFA≥300 cm2且CLcr≥90 mL/min作为剂量调整标准。
临床怎么用
- 对肥胖结直肠手术患者,可考虑结合术前CT体成分(SFA)和肾功能(CLcr)评估预防剂量是否充分。
- 现行按体重≥120 kg升级剂量的策略可能低估部分患者的剂量不足风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether CT-derived body composition and kidney function better predict cefazolin concentrations at the surgical site than body weight alone in patients with obesity undergoing colorectal surgery. BACKGROUND: Current cefazolin prophylaxis guidelines recommend dose escalation from 2 g to 3 g in patients weighing ≥120 kg. However, body weight inconsistently reflects antibiotic distribution at the surgical site. METHODS: We conducted a prospective study of adults with obesity undergoing elective colorectal surgery who received cefazolin prophylaxis and had preoperative CT imaging. Cefazolin concentrations were measured in plasma, subcutaneous adipose tissue, and colorectal tissue during surgery. CT-derived body composition metrics were quantified using analytic morphomics. Modeling and simulations were used to identify predictors of target attainment in subcutaneous tissue. Agreement between revised physiologic dosing criteria and current weight-based guidance was assessed in both a derivation cohort and an independent external cohort. RESULTS: Among 153 patients, 58 were included in model development and 95 in prospective evaluation. Weight and BMI did not improve model performance. Subcutaneous fat area (SFA) predicted tissue exposure, while creatinine clearance (CLcr) predicted elimination. Current weight-based dosing achieved 78%-84% target attainment. A revised framework of SFA ≥500 cm2 or ≥300 cm2 with CLcr ≥90 mL/min identified an additional 10%-14% of patients for dose adjustment, improving identification of underdosing-related SSI risk without unnecessary antibiotic use. CONCLUSIONS: Cefazolin exposure is better explained by local adiposity and kidney function than by the current ≥120 kg weight-based dosing threshold.
引用
- Pai MP, Matvekas A, Sullivan J, et al. Challenging Weight-Tiered Antibiotic Prophylaxis in Obese Patients Undergoing Colorectal Surgery Using CT-Derived Body Composition. Clin Infect Dis. 2026. PMID: 42320895. doi:10.1093/cid/ciag383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。